253 related articles for article (PubMed ID: 24116901)
1. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Havari E; Turner MJ; Campos-Rivera J; Shankara S; Nguyen TH; Roberts B; Siders W; Kaplan JM
Immunology; 2014 Jan; 141(1):123-31. PubMed ID: 24116901
[TBL] [Abstract][Full Text] [Related]
2. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
3. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
Dons EM; Raimondi G; Zhang H; Zahorchak AF; Bhama JK; Lu L; Ezzelarab M; Ijzermans JN; Cooper DK; Thomson AW
Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
[TBL] [Abstract][Full Text] [Related]
5. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.
Haas J; Würthwein C; Korporal-Kuhnke M; Viehoever A; Jarius S; Ruck T; Pfeuffer S; Meuth SG; Wildemann B
Front Immunol; 2019; 10():1204. PubMed ID: 31214176
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.
Wiendl H; Kieseier B
Nat Rev Neurol; 2013 Mar; 9(3):125-6. PubMed ID: 23358486
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
10. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Brown JW; Coles AJ
Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
[TBL] [Abstract][Full Text] [Related]
12. Mode of action and clinical studies with alemtuzumab.
Jones JL; Coles AJ
Exp Neurol; 2014 Dec; 262 Pt A():37-43. PubMed ID: 24792641
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
Buggins AG; Mufti GJ; Salisbury J; Codd J; Westwood N; Arno M; Fishlock K; Pagliuca A; Devereux S
Blood; 2002 Sep; 100(5):1715-20. PubMed ID: 12176892
[TBL] [Abstract][Full Text] [Related]
14. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
[TBL] [Abstract][Full Text] [Related]
15. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
[TBL] [Abstract][Full Text] [Related]
16. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
17. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
18. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]